Antibiotic resistant Staphylococcus aureus is a major public health concern effecting millions of people annually. Medical science has documented completely untreatable S. aureus infections. These strains are appearing in the community with increasing frequency. New diagnostic and therapeutic options are needed to combat this deadly infection. Interestingly, around 50% of the proteins in S. aureus are annotated as hypothetical. Methods to select hypothetical proteins related to antibiotic resistance have been inadequate. This study uses differential gene expression to identify hypothetical proteins related to antibiotic resistant phenotype strain variations. We apply computational tools to predict physiochemical properties, cellular location, sequence-based homologs, domains, 3D modeling, active site features, and binding partners. Nine of 23 hypothetical proteins were <100 residues, unlikely to be functional proteins based on size. Of the 14 differentially expressed hypothetical proteins examined, confident predictions on function could not be made. Most identified domains had unknown functions. Six hypothetical protein models had >50% confidence over >20% residues. These findings indicate the method of hypothetical protein identification is sufficient; however, current scientific knowledge is inadequate to properly annotate these proteins. This process should be repeated regularly until entire genomes are clearly and accurately annotated.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429968 | PMC |
http://dx.doi.org/10.6026/97320630013104 | DOI Listing |
PLoS One
January 2025
Department of Microbiology, UT Southwestern Medical Center, Dallas, TX, United States of America.
Unraveling the metabolism of Treponema pallidum is a key component to understanding the pathogenesis of the human disease that it causes, syphilis. For decades, it was assumed that glucose was the sole carbon/energy source for this parasitic spirochete. But the lack of citric-acid-cycle enzymes suggested that alternative sources could be utilized, especially in microaerophilic host environments where glycolysis should not be robust.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Background: Differences in task-fMRI activation have recently been found to be related to neuropathological hallmarks of AD. However, the evolution of fMRI-based activation throughout AD disease progression and its relationship with other biomarkers remains elusive. Applying a disease progression model (DPM) to a multicentric cohort with up to four annual task-fMRI visits, we hope to provide a deeper insight into these relationships.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, San Francisco, and San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Lifestyle and metabolic multi-domain approaches targeting several risk factors at a time are increasingly being recognized as critical for dementia prevention since single-factor approaches and one-size-fits-all interventions often fall short in substantially reducing the dementia burden. Therefore, we compared the effectiveness of several hypothetical midlife lifestyle interventions considered singly and in combination across two health approaches: high-risk subpopulations (targeted) and general population (untargeted).
Method: Data came from the combined 2006 and 2008 biomarker samples of the Health and Retirement Study (HRS, N = 12,219).
Background: The A4 Study (NCT02008357) was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, assessing the safety and efficacy of solanezumab in preclinical Alzheimer's Disease (AD). We previously reported on the baseline regional flortaucipir (FTP) profiles in this study. Here, we present the longitudinal tau profiles.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Eli Lilly and Company, Indianapolis, IN, USA.
Background: The A4 Study (NCT02008357) was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, assessing the safety and efficacy of solanezumab in preclinical Alzheimer's Disease (AD). We previously reported on the baseline regional flortaucipir (FTP) profiles in this study1. Here, we present the longitudinal tau profiles.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!